Biotech Business - September 20, 2019
Biosimilars: Opportunities & Challenges
The development and use of biosimilars continues to grow in the Nordic countries, as well as the rest of Europe, and experts are excited about their potential. But there is a thicket of legal issues and regulations that companies have to navigate to get their drugs to the market. A biosimilar is almost identical to […]
Legal Advice article - May 14, 2019
Dignitana efforts prompt landmark legislation
The company announces that HB3984, the bill providing coverage for scalp cooling that the company initiated in February with Texas State legislators, was passed in the Texas House of Representatives on Friday. The Bill now moves to the Senate where it will be introduced by Sen. Angela Paxton. Once passed in the Senate, the Bill […]
Legal Advice article - June 7, 2018
Lundbeck reaches voluntary agreement with US Department of Justice
H. Lundbeck announces that its U.S. subsidiary Lundbeck LLC has reached an agreement in principle to resolve the U.S. Department of Justice (DOJ) investigation related to Lundbeck LLC’s relationship with and donations to independent patient assistance charitable foundations. As part of the agreement, Lundbeck LLC will pay DOJ USD 52.6 million (approximately DKK 336 million). […]
Global report - September 3, 2017
First excessive pricing investigation on the pharma sector
The European Commission (EC) opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines. The formal investigation address concerns that Aspen Pharma has engaged in excessive pricing concerning five life-saving cancer medicines. The Commission will investigate whether Aspen has abused a dominant market position in breach of EU antitrust rules. “When we get sick, […]
Legal Advice article - March 27, 2017
Asset Value
For life science companies, putting a price on their most valuable resources – ideas, research, proposals and prototypes – can be difficult. Yet the need to protect these assets is critical to preserving a company’s overall value and its ability to move any research forward. Since intellectual property often is a life science company’s primary […]
In a new job - January 20, 2017
Carl Josefsson appointed President of the Boards of Appeal
The Administrative Council (AC) of the European Patent Organisation has appointed Carl Josefsson from Sweden as the first President of the Boards of Appeal (BoA). A new location for the BoA was also approved by the Member States. Both measures are being taken as an important part of the institutional reforms adopted in June 2016 to […]
